The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Investigation

• Publication date

  2003-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI16603PMCID PMC164283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Time-dependent suppression of melanoma metastases and natural killer cell activation by interferon

  2004cited by this paper
• Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.

  2002cited by this paper
• Interferon alfa-2a for melanoma metastases.

  2002cited by this paper
• Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells

  2002cited by this paper
• Interferon-alpha in tumor immunity and immunotherapy.

  2002cited by this paper
• Serum imbalance of cytokines in melanoma patients

  2001cited by this paper
• Interferons α and β as Immune Regulators—A New Look

  2001cited by this paper
• Interferons alpha and beta as immune regulators--a new look.

  2001cited by this paper
• Stat1-independent regulation of gene expression in response to IFN-γ

  2001cited by this paper
• Biologic consequences of Stat1-independent IFN signaling

  2001cited by this paper
• Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.

  2000cited by this paper
• L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Retroviral Expression in Embryonic Stem Cells and Hematopoietic Stem Cells

  2000cited by this paper
• Distinct Requirements for IFNs and STAT1 in NK Cell Function1

  2000influential reference
• IFNalpha/beta promotes cell survival by activating NF-kappa B.

  2000cited by this paper
• IFNα/β promotes cell survival by activating NF-κB

  2000cited by this paper
• Detection of intracellular phosphorylated STAT-1 by flow cytometry.

  1999cited by this paper
• Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

  1999cited by this paper
• Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides.

  1999cited by this paper
• A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.

  1999cited by this paper
• Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons

  1999cited by this paper
• Signal transduction in the interferon system.

  1998cited by this paper
• Jaks and STATs: biological implications.

  1998cited by this paper
• Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

  1998influential reference
• IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs.

  1998cited by this paper
• Two gamma-interferon-activation sites (GAS) on the promoter of the human intercellular adhesion molecule (ICAM-1) gene are required for induction of transcription by IFN-gamma.

  1998cited by this paper
• Down-Regulation of Tumoricidal NK and NK T Cell Activities by MHC Kb Molecules Expressed on Th2-Type γδ T and αβ T Cells Coinfiltrating in Early B16 Melanoma Lesions

  1998cited by this paper
• Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.

  1998cited by this paper
• A new mouse model of experimental melanoma for vaccine and lymphokine therapy.

  1998cited by this paper
• Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

  1998cited by this paper
• Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions.

  1998cited by this paper
• Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.

  1997cited by this paper
• Targeted Inhibition of Interferon-γ-dependent Intercellular Adhesion Molecule-1 (ICAM-1) Expression Using Dominant-Negative Stat1*

  1997cited by this paper
• IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo.

  1997cited by this paper
• Physical association between STAT1 and the interferon‐inducible protein kinase PKR and implications for interferon and double‐stranded RNA signaling pathways

  1997cited by this paper
• Enhanced In Vivo Sensitivity of In Vitro Interferon-Treated B16 Melanoma Cells to CD8 Cells and Activated Macrophages

  1996cited by this paper
• Antitumor Functions of Natural Killer Cells and Control of Metastases

  1996cited by this paper
• Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.

  1996cited by this paper
• Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues.

  1996cited by this paper
• Potential uses of interferon alpha 2 as adjuvant therapy in cancer.

  1995cited by this paper
• Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.

  1995cited by this paper
• Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family.

  1994cited by this paper
• Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver.

  1994cited by this paper
• Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

  1994cited by this paper
• Production of high-titer helper-free retroviruses by transient transfection.

  1993cited by this paper
• A common nuclear signal transduction pathway activated by growth factor and cytokine receptors.

  1993cited by this paper
• Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852.

  1993cited by this paper
• Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy

  1992cited by this paper
• Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma.

  1991cited by this paper
• Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control.

  1988cited by this paper
• Immunological effects of recombinant interferon alfa‐2a in patients with disseminated melanoma

  1986cited by this paper
• The complete nucleotide sequence of mouse 28S rRNA gene. Implications for the process of size increase of the large subunit rRNA in higher eukaryotes.

  1984cited by this paper
• Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.

  1983cited by this paper
• A severe combined immunodeficiency mutation in the mouse

  1983cited by this paper
• Enhanced expression of melanoma-associated antigens and beta 2-microglobulin on cultured human melanoma cells by interferon.

  1982cited by this paper
• Development of a new melanoma model in C57BL/6 mice.

  1982cited by this paper
• Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.

  1982cited by this paper

• Combined carbon ion radiotherapy and immunotherapy: leveraging the immunological advantages of carbon ion

  2026cites this paper
• Borrelia burgdorferi sensu lato inhibits CIITA transcription through pSTAT3 activation and enhanced SOCS1 and SOCS3 expression leading to limited IFN-γ production.

  2025cites this paper
• A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.

  2024cites this paper
• Proteomic Dynamics of Multidrug Resistance Mechanisms in Lucena 1 Cell Line

  2024cites this paper
• Inhibition of SIRT7 promotes STAT1 activation and STAT1-dependent signaling in hepatocellular carcinoma.

  2023cites this paper
• A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence

  2023cites this paper
• Stat1 is an inducible transcriptional repressor of neural stem cells self-renewal program during neuroinflammation

  2023cites this paper
• Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells

  2022cites this paper
• Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy

  2021cites this paper
• An insertion variant of MGMT disrupts a STAT1 binding site and confers susceptibility to glioma

  2021cites this paper
• The effect of acute heat stress on the innate immune function of rainbow trout based on the transcriptome.

  2021cites this paper
• New Treatment New Complication – Mini Review

  2020cites this paper
• Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.

  2020cites this paper
• The potential and controversy of targeting STAT family members in cancer.

  2020cites this paper
• Interferon α in cancer immunoediting: From elimination to escape

  2020cites this paper
• Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex–mediated STAT1 downregulation

  2020cites this paper
• Adverse kidney effects of immunotherapies

  2020cites this paper
• Nephrotoxicity in cancer treatment: An overview

  2020cites this paper
• From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy.

  2019cites this paper
• A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer

  2019cites this paper
• The adverse kidney effects of cancer immunotherapies

  2018cites this paper
• Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

  2018cites this paper
• Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

  2018cites this paper
• Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration

  2017cites this paper
• STATs in NK-Cells: The Good, the Bad, and the Ugly

  2017cites this paper
• Role of interferon in melanoma: old hopes and new perspectives

  2017cites this paper
• Effects of total flavonoids of sea buckthorn (Hippophae rhamnoides L.) on cytotoxicity of NK92-MI cells

  2017cites this paper
• Monocyte and interferon based therapy for the treatment of ovarian cancer.

  2016cites this paper
• Cytokine & Growth Factor Reviews

  2016cites this paper
• INFα-2b inhibitory effects on CD4+CD25+FOXP3+ regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts

  2016cites this paper
• Host STAT2/type I interferon axis controls tumor growth

  2015cites this paper
• Type I interferons in anticancer immunity

  2015cites this paper
• Who benefits most from adjuvant interferon treatment for melanoma?

  2015cites this paper
• ROLE OF STAT3 IN HUMAN NK CELL FUNCTIONS

  2015cites this paper
• Interferons and their stimulated genes in the tumor microenvironment.

  2014cites this paper
• Intracellular Poly(I:C) Initiated Gastric Adenocarcinoma Cell Apoptosis and Subsequently Ameliorated NK Cell Functions

  2014cites this paper
• Current Systemic Therapies for Melanoma

  2014cites this paper
• Modulation of antitumour immune responses by intratumoural Stat1 expression

  2013cites this paper
• STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin?

  2013cites this paper
• Current Status and Future Directions

  2013cites this paper
• Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells

  2013cites this paper
• Cancer immunotherapy: current status and future directions.

  2013cites this paper
• Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

  2013cites this paper
• Activation Mechanisms of Natural Killer Cells during Influenza Virus Infection

  2012cites this paper
• Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

  2012cites this paper
• STAT Signaling in Cancer Prevention

  2012cites this paper
• MicroRNAs and STAT interplay.

  2012cites this paper
• Dynamic regulation of microRNA expression following Interferon-γ-induced gene transcription

  2012cites this paper
• From Concept to the Clinics: Development of Cancer Therapeutics

  2011cites this paper
• The Jak-STAT Signal Transduction Pathway in Melanoma

  2011cites this paper
• Immunomodulatory cytokines as therapeutic agents for melanoma.

  2011cites this paper
• Neoadjuvant therapy for high‐risk bulky regional melanoma

  2011cites this paper
• Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

  2011cites this paper
• A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

  2011cites this paper
• Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

  2011cites this paper
• Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells

  2011cites this paper
• Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy

  2011cites this paper
• Proteomic analysis reveals a novel mechanism induced by the leukemic oncogene Tel/PDGFRβ in stem cells: activation of the interferon response pathways.

  2010cites this paper
• Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells

  2010cites this paper
• Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.

  2010cites this paper
• Nano-enabled Platforms for Metastatic Malignant Melanoma

  2010cites this paper
• From Concept to the Clinics: Development of Novel Large Molecule Cancer Therapeutics

  2010cites this paper
• STAT1 and pathogens, not a friendly relationship

  2010cites this paper
• Neoadjuvant Approaches in Melanoma

  2009cites this paper
• Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines

  2009cites this paper
• Predictors of response to interferon therapy

  2009cites this paper
• Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells

  2009cites this paper
• Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.

  2008cites this paper
• Effects of High-Dose IFNα2b on Regional Lymph Node Metastases of Human Melanoma: Modulation of STAT5, FOXP3, and IL-17

  2008cites this paper
• PTP1B and TC-PTP: regulators of transformation and tumorigenesis

  2008cites this paper
• STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.

  2008cites this paper
• IFN-α-2b–Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m2

  2008cites this paper
• Mechanisms of Rejection of High Grade B cell Lymphoma in Mice

  2008cites this paper
• Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1.

  2008cites this paper
• Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.

  2008cites this paper
• Activated stat-3 in melanoma.

  2008cites this paper
• Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling.

  2008cites this paper
• VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines

  2008cites this paper
• Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α

  2008cites this paper
• Predicting and Increasing Response of Melanoma to Interferon Therapy

  2008cites this paper
• STAT protein regulation of Foxp3 expression and inflammatory cytokine production in T helper cell subsets

  2008cites this paper
• of Patients with Melanoma: Dose-Response Effects of Systemic IFNa Therapy

  2008cites this paper
• Antitumorale Wirkungen von TypI Interferon

  2008cites this paper
• Understanding Interferon: Translating Biologic Advances into Clinical Progress

  2008cites this paper
• Chapter 52 – Interferons

  2008cites this paper
• The Type I Interferon System With Emphasis on Its Role in Malignancies

  2007cites this paper
• IFN-α-Induced Signal Transduction, Gene Expression, and Antitumor Activity of Immune Effector Cells Are Negatively Regulated by Suppressor of Cytokine Signaling Proteins1

  2007cites this paper
• Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-α Compared with Immune Effector Cells

  2007cites this paper
• Altered macrophage differentiation and immune dysfunction in tumor development.

  2007cites this paper
• Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.

  2007cites this paper
• Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b

  2007cites this paper
• STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha

  2007cites this paper
• Modulation of SignalTransducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFN A 2 b

  2007cites this paper
• Natural killer cell‐mediated ablation of metastatic liver tumors by hydrodynamic injection of IFNα gene to mice

  2007cites this paper
• Experimental Models of Cytokines and Cancer Prevention

  2007cites this paper
• Regulated by Suppressor of Cytokine Immune Effector Cells Are Negatively Expression , and Antitumor Activity of-Induced Signal Transduction , Gene

  2007cites this paper
• STAT1 acts as a tumor promoter for leukemia development.

  2006cites this paper
• Functional expression of human type I interferon receptors in the mouse liver.

  2006cites this paper